Roberto Mazzanti, M.D
Professor of Medical Oncology


  • M.D. thesis:  1974, July 25th, at University of Florence, Italy, degreed with Honors.
  • Postgraduate School in Gastroenterology:  1979, with Honors
  • Senior Researcher: 1981-1993, at School of  Medicine , University of Florence, Department of Internal Medicine, Liver Unit.


Born in Florence, Italy, 1949, he attended Medical and Postgraduate School in University of Florence becoming M.D. and Specialist in Gastroenterology. Lieutenant in the Italian Army as Medical Doctor. After that service he have been working at University Hospitals of Parma and Florence, on liver diseases and cancer for almost his career. Appointed Full Professor of Medicine, he have been teaching Internal Medicine to medical, nurse and technician students for many years and, subsequently, he had the Chair of Medical Oncology that he kept at the University of Florence to December 2013 when retired and moved to USA. 

The President of the Repubblica Italiana appointed him Ufficiale (Officer) of the Ordine al Meritodella Repubblica Italiana.

He is acting as referee for many international journal such as: Hepatology, Gut, Oncogene, International J. of Cancer, Biochem. Pharmacol., Word J. Gastroenterology and others.

He is a member of the International Scientific Board of W. J. Gastroenterology and also W.J. of Clinical Oncology.

Research Interest

Research career of R.M. has concerned pathophysiology of the liver, gastrointestinal diseases and in the last 20 years his interests as scientist have moved to cancer and particularly to the understanding of how cancer cells become resistant to anticancer drugs and to ionizing radiation. In addition, he had been working on treatment of liver cancer and proteomics of colon cancer.

The most recent interests concern the effect of the acquiring of the multiple drug resistance (MDR) phenotype of cancer cells on mechanisms of cell resistance to several damaging agents and the relationship between MDR phenotype and cancer angiogenesis.

Main interests of research have been the important issue concerning drug resistance and cancer and liver diseases.  Concerning this topics he have discovered that the expression of the MDR1 phenotype in cancer cells is associated with the expression of P-glycoprotein also in mitochondria membrane focusing on these important organelles as playing a central role in affecting drug sensitivity to anticancer drugs.

As regards primary liver cancer or hepatocellular carcinoma, he has accumulated during his career a long practice on how dealing with such lethal disease, that commonly it is associated with liver cirrhosis. He studied mechanisms by which hepatitis C infection can increase the risk for HCC in humans by triggering liver angiogenesis in addition to well known consequences of chronic inflammation such as necrosis, fibrosis and liver regeneration.


Academic career:

  • M.D. thesis:  1974, July 25th, at University of Florence, Italy, degree with Honors.
  • Postgraduate School in Gastroenterology: 1979, with Honors
  • Senior Researcher: 1981-1993, at School of  Medicine, University of Florence, Department of Internal Medicine, Liver Unit.
  • Associate Professor of Medicine: 1993-1996, School of Medicine, University of Parma, Internal Medicine.
  • Associate Professor of Medicine, 1996-2001, School of Medicine, University of Florence, Internal Medicine.
  • Full Professor of Medicine: 2001- now, School of Medicine, University of Florence, Internal Medicine.
  • Full Professor of Medical Oncology 2008 now.
  • Director of the Post Graduate School in Oncology of the University of Florence since October 2002.  
  • Full Professor: 2001 – 2013 of Medicine, Chair of  Medical Oncology;
  • Director of 2nd Unit of OncologiaMedica of AziendaOspedaliero-UniversitariaCareggi  from 2008 up to 31st  December, 2013

Awards and Experience Abroad:

Roberto Mazzanti, won a Welcome Trust Fellowship and between November 1984 to April 1986 worked at the Royal Free Hospital , London, UK, with Prof. Dame Sheila Sherlock first and Prof. Neil McIntyre then.

In 1988 he spent near 10 months at Tufts University, Boston, MA, working with Prof. Irwin M. Arias. In this period of time he was awarded with the Annual Prize for Research by the American Liver Foundation for his studies on the multi drug resistant phenotype in cancer cells (Chicago, November 5th, 1988).


  1. Gentilini  P., Laffi  G.,Stefani  P.,  Masi R.,  Buzzelli  G.,  Salvadori G., Mazzanti R.e  Moggi A.: Early functional modifications  of the  kidney in  chronic hepatitis.  In:  Gentilini P.,  Popper H.,  Teodori  U.(Eds.): ChronicHepatitis.  pagg.69-76,  Karger, Basilea, 1976. (senza IF)
  2. MazzantiR.., Arcangeli A.,  Salvadori G., Smorlesi C.,  Di Perri   T.,  Auteri A.,  Boggiano C.A.,  Pippi L.,  Toti M.,  BOncompagni P.,  Angioli D., Caremani  M., Magnolfi F., Camarri E.,  Motta R., Forconi A., Candidi  Tommasi A., Lomi M.,  e Soldi A.: On  the anti-steatosic'   effects of  S-adenosyl-methionine in variouschronicliverdiseases.  Multicentrestudy.  Curr.Ther.Res., 25:25-34, 1979. (IF:0,791)
  3. ChiarantiniE.,  Arcangeli   A.,  Mazzanti  R.,  Romagnoli  P., Moscarella S. e Gentilini  P.: Ethynil-estradiolinducedcholestasismorphological and  functionalaspects.  In: Gentilini  P., Popper H.,  Sherlock S., Teodori U.(Eds.):  Problems in intrahepatic cholestasis.pagg.102-110, Karger, Basilea, 1979. (senza IF)
  4. Gentilini  P., Laffi  G., Buzzelli G.,Cappelli G.,  Stefani P.,   Smorlesi C., La Villa G.  e Mazzanti R.: Functional renal alterations'   in intrahepatic cholestasis.  In.   Gentilini P., Popper H., Sherlock  S.,   Teodori  U.(Eds.):   Problems   in  intrahepatic   cholestasis.  pagg.125-131, Karger, Basilea, 1979. (senza IF)
  5. ChiarantiniE.,  Mazzanti R., Chieca R., Orlandini  F., Arena U.,   Coletta  D. e  Gentilini P.:  Patogenesis and  reboundphenomenon  in  ethynil-estradiolcholestasis in rats.  Agressologie, 23:25-28, 1982. (senza IF)
  6. Giusti  G., Ruggiero G.,Galanti B., Piccinino F.,  Sagnelli E.,   Gallo G., Arico' S., Bellei  M., Bernardi M., Chiaramonte M., Colombo  M., Del  Ninno E.,  Iannuzzi C.,  Maio G.,  Manenti F.,  Marzillo G.,   Martinez D., Mastroroberto L., Mazzanti R., Pagliaro L., Pinzello G.,  Sacchi  G., Schiraldi  O., Tolentino  P., Zancan  L.: Chronicactivehepatitis in Italy:  a multicentricstudy of  clinical and laboratory  data of 1154 cases.  Hepatogastroenterol., 30:126-130, 1983. (IF:0,833)
  7. Moscarella S., Laffi G., Buzzelli G., Mazzanti R., Caramelli L. eGentilini  P.: Expiredhydrocarbons in  patients with  chronicliverdisease.  Hepatogastroenterol., 31:60-63, 1984.(IF:0,833)
  8. Giusti  G., Piccinino F.,Galanti B., Sagnelli E.,  Ruggiero G.,  Gallo G., Arico' S., Bellei  M., Bernardi M., Chiaramonte M., Colombo   M., Del  Ninno E.,  Iannuzzi C.,  Maio G.,  Manenti F.,  Marzillo G.,  Martinez D., Mastroroberto L.,  Mazzanti R., Pagliaro L., Pinzello G.,  Sacchi G.,  Schiraldi O., Tolentino P.,  Zancan L.: Immunosuppressivetherapy  in chronicactivehepatitis.  a multicentricretrospectivestudy on 867 patients.  Hepatogastroenterol., 31:24-29, 1984. (IF:0,833)
  9. Buzzelli G., ChiarantiniE., Mazzanti R.Arcangeli A., Orioli S.   e Gentilini  P.: The  BSF  loading test  in  chronic alcoholic  liver  diseases.  Boll.Soc.It.Biol.Sper., 60:543-548, 1984. (senza IF).
  10. Bechi P.,Carcangiu M.L.  , Mazzanti R., Pacini P.  Romagnoli P. e   Tonelli  L.:  An  insightinto  post-gastrectomy  "alkalinerefluxgastritis".  Ital.J.Surg.Sci., 16:85-92, 1986. (senza IF).
  11. Bechi  P., Mazzanti  R., ArenaU., Gregorini  M., Naspetti  R. é   Arcangeli G.: Bile acid pattern in gastricjuice and gallstonesafterpartialgastrectomy. I.R.C.S.Med.Sci., 14:130-131, 1986. (senza IF)
  12. Buzzelli  G., Smorlesi C.,Mazzanti R., Pampana A.,  Matassi L.,   Simondi  P. e  Gentilini  P.: Chemotherapy of  primary and  secondarylivercancer: isitusefull? Chemioterapia, 5:173-176, 1986. (senza IF).
  13. ChiarantiniE., Mazzanti R.,  Buzzelli G., Chieca R., Coletta D.,   Orlandini F., Romeo D. e  Arena  U.: Action of acute ethanolintake on ratbiliarysecretion.  Effect of epomediol. Il Farmaco, 41:307-312,1986. (senza IF)           
  14. Mazzanti R.,Chiarantini E., Arena U., Moscarella  S. e Buzzelli   G.: Can serum bile acid  determinationsubstitute BSP loading test in   detecting  and monitoringchronicliverdisease?  Boll.   Soc.It.  Biol.  Sper., 62:219-226, 1986. (senza IF)
  15. Moscarella  S., Chieca R.,Mazzanti R.Chiarantini  E., Zignego  A.L. e Gentilini P.: Glutathionelevels in drinkers' livers.  Front.  Gastrointest.  Res., 9:158-166, 1986. (senza IF)
  16. Mazzanti R. ,  Jenkins W.J.: Effect of chronic  ethanol intake on   the enterocyte turnover in rats.  Gut, 28:52-55, 1987. (IF:6,323)
  17. Mazzanti R.,  Debnam  E.S.,  Jenkins W.  J.:  Effect of  chronic   ethanol intake on lactase activity and active galactose absorption in  rat small intestine.  Gut, 28:56-60, 1987.(IF:6,323)
  18. Mazzanti R.Srai K.S., Debnam  E.S., Boss A.M. and Gentilini P.:  The  effect of chronic ethanol consumption on iron absorption in rats.   Alcohol and Alcoholism, 22:47-52, 1987.(IF:1,816)
  19. The Italian Liver Cirrhosis  Project: Pagliaro L., Spina G.P.,...Mazzanti al.:  Reliability of endoscopy  in the  assessment of  variceal features.  J. Hepatol., 4:93-98, 1987.  (IF: 4,974)
  20. Bechi P.,Amorosi A., Mazzanti R., Romagnoli P.  and Tonelli L.:  Gastric histology and fasting  bile reflux after partial gastrectomy.  Gastroenterology, 93:335-343, 1987.(IF:13,440)
  21. Gentilini P.,Mazzanti R., Buzzelli G., Baronti  E., Gialdini D.   et al.   Alcoholicliverdisease in Tuscany.  Preliminary results of  a multicentre study.  Ital.  J. Med., 3:83-87, 1987. (senza IF).
  22. Bechi  P., Mazzanti R.,Castagnoli  A., Arena U., Naspetti  R. and   Buccarelli  A.: Enterogastricrefluxdetected  by cholescintigraphy.   Assessment  of  bile  acids  in gastric  aspirates,  and  gastric  pH  monitoring:  Comparison   of  results  in   partially  gastrectomized   patients.  In:  Siewert J.R. and  Holscher A.H.  (Eds.):  Dis Esophagus.    1299-1303, 1088. (IF:0,603)
  23. Carini R.,Mazzanti  R,  Biasi F.,  Chiarpotto  E., Marno  G.,   Moscarella S., Gentilini  P., Dianzani M.U. and  Poli G.: Fluorescentaldehyde-proteinadducts  in the  bloodserum of  healthyalcoholics.   Advances in the Biosciences, 71:61-64.1988. (senza IF)
  24. MazzantiR., Pinzani  M., Zignego  A.L., Buzzelli  G., Romanelli   R.G., Foschi M., Galaska R.  and Gentilini P.: Effects of recombinant   human  gamma-interferon on  advanced  hepatocellular carcinoma.   In:   Gentilini  P., Dianzani  M.U.( Eds.):  Pathophysiology of  the liver,pagg.  227-235, Excerpta Medica, Amsterdam, 1988. (senza IF)
  25. Bechi  P., Amorosi A.,Mazzanti R.Buccarelli A.,  Pantalone D.   and  Cortesini  C.:  Short-term  effects of  bile  diversion  on  the   postgastrectomy gastric  histology. Dig.  Dis.   Sci., 33:1288-1296,  1988. (IF:1,303)
  26. Bechi P.,  Naspetti R., Mazzanti R., Castiglione  G., Tonelli P.,   Amorosi  A.,  Tonelli  L.:  Billroth I  versus  Billroth  II  partial   gastrectomy  in  thetreatmentofgastriculcer. It. J.Surg. Sci., 18:339-346, 1988. (senza IF)
  27. Mazzanti R., Moscarella S.,  Bensi G., Altavilla E. and GentiliniP.: Hepatic lipid peroxidation and aldehyde dehydrogenase activity inalcoholic and  non alcoholic liver disease.   Alcohol and Alcoholism,24, 121-128, 1989. (IF:1,816)
  28. MazzantiR., Caramelli  L.,  Georgudis  E., Moscarella  S.  and  Gentilini P.:  Effect of chronic  alcoholism on hepatic  alcohol- and aldehyde-dehydrogenase  activities  in man. Boll. SocIt.Biol. Sper. LXV, 465-472, 1989. (senza IF)
  29. Moscarella  S.,  Mazzanti  R.,Gentilini  P.:  Role  of  lipid peroxidation and antioxidant in alcoholic  liver disease in man.  In:Poli  G., Cheeseman  K.H., Slater  T.F., Dianzani  M.U.  (Eds)  "Free Radicals in Liver  Pathology" . Advances in the  Biosciences, vol.  76;pp.  275-280, 1989. Pergamon Press, Oxford. (senza IF)
  30. Al  Balool F.,  Debnam E.S.  andMazzanti  R.: Acute  and chronic exposure to  ethanol and   the electrophysiology  of the  brush border membrane of rat small intestine.  Gut, 30, 1698- 1703, 1989. (IF:6,323)
  31. Moscarella  S.,Buzzelli  G.,  Mazzanti  R.and  Gentilini  P. Lipoperoxidative processes and antioxidants  in chronic liver disease in  different  age groups.   In:  The  liver, metabolism  and  ageing Woodhouse K.W., Yelland C., James O.   F., W. Eds.  1989; pag.  151- 160. (senza IF)
  32. MazzantiR.,Gatmaitan Z., Croop  J. M., Shu H.  and Arias I.M   Quantitative   image  analysis   of   rhodamine   123  transport   by Adriamycin-sensitive and  resistant NIH 3T3 and  human hepatocellular  carcinoma (Alexander) cells.  J. Cell  Pharmacol.  1; 50-56; 1990. (senza IF)
  33. Mazzanti R.,  Moscarella S. and Gentilini P. Chronic alcohol abuse,   lipid peroxidation  and    liver  damage in man.   In: Advances  in Free  Radicals  in disease  II.  Tomasi  A., Ursini  F., Vannini  V.; Eds.  CLEUP Ed.  Padova. pp 193-198; 1990. (senza IF)
  34. Bechi P., Balzi M., Becciolini  A., Amorosi A., ScublaE., V.,  Mazzanti  R.,   Tonelli  P.,  and  Cortesini   C.  Gastric  cell   proliferation  kinetics and  bile reflux  after partial  gastrectomy.   The Am. J. Gastroenterol.  86; 1424-1432; 1991. (IF: 3,953)
  35. Arias I.M., Gatmaitan Z., Mazzanti R., Shu H.,  Kumamoto Y. Structure and function of P-glycoprotein in the normal liver and intestine. In: Xenobiotics and Cancer.  L. ErnsterEdt ., Taylor and Francis LTD. London , 1991:pag 229-239. (senza IF)
  36. Lippi G., Fedi S., Grassi M., Rosi E., Alessandriello Liotta A.,   Fontanelli A., Cella A.P., Mazzanti R..  Acute phase proteins in   alcoholics with or without liver injury. It. J. Gastroenterol. 24;  383-385, 1992.  (IF: 0,589)
  37. Mazzanti R., Croop JM, GatmaitanZ., Budding M., Steiglitz K.,  Arceci  R.  and  Arias  IM.   Benzquinamide  inhibits  P-glycoprotein  mediated drug  efflux and potentiates anticancer  agent cytotoxicity in multidrug resistant cells.  Oncology Res.   (già CancerCommun.) 4; 359-365, 1992.  (IF:1,476)
  38. Bechi P., Amorosi A., Mazzanti R., Dei R., Bianchi S., Mugnai L.,Masini E.   Reflux related gastric  mucosal injury is  associated with    increased  mucosal histamine  content  in humans.   Gastroenterology,   104; 1057-1063, 1993.  (IF:13,440)
  39. Bechi P.,Pucciani  F.,  Baldini F., Cosi F., Falciai R., Mazzanti  R. et  al.,    Long-termambulatoryenterogastricrefluxmonitoring.  Validation of a new fiberoptictechnique. Dig.  Dis.  Sci.38; 1297-1306, 1993. (IF: 1,438)
  40. Monsacchi L., and Mazzanti R. Epidemiologia e historianatural del carcinoma hepatico.   ReviewArticle. Rev.Cancer (Madrid)(Spagnolo). 7:29-33; 1993.  (senza IF)
  41. Mazzanti R. La colestasi intraepatica: aspetti clinici e cenni di terapia. Gastroenterology and Hepatology 1/93; 21-23; 1993. (senza IF).
  42. Mazzanti R., Monsacchi L., and  Gentilini P., Epidemiology and natural history of hepatocellular carcinoma. Review Article. Forum, Trends in Exp. &Cli. Med. 4: 161-171; 1994. (senza IF)
  43. Zignego A.L., Foschi M., Laffi. G., ... Mazzanti R. et al. “Inapparent” hepatic B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. Hepatology ,19; 577-582; 1994. (IF:9,825) 
  44. Mazzanti R., Fantappié O., Fabrizio P., Monsacchi L.,  Gentilini P. Effect of the induction of multiple drug resistance on  susceptibility to lipid peroxidation in a human hepatocellular carcinoma cell line. In Advances in Free Radicals in disease. Tomasi A., Ursini F., and Vannini V. Eds.  CLEUP Edizioni, Padova, pagg. 159-166; 1994.  (senza IF)
  45. Mazzanti R., Fantappiè O., Kamimoto Y, Gatmaitan Z., Gentilini P., and Arias I.M. Bile acid inhibition  of P-glycoprotein mediated transport in multidrug resistant cells and rat liver canalicular membrane vesicles. Hepatology, 20:170-176; 1994. (IF:9,825)
  46. Mazzanti R.  Treatment of hepatocellular carcinoma. Review Article. AlpeAdria J. Med.  49:651-661; 1994. (senza IF).
  47. Gentilini P., Romanelli R.G., Foschi M., Mazzanti R.Pathogenetic mechanisms of intrahepatic cholestasis. In: Fat storing cells and Liver fibrosis. Surrenti C.,  Casini A.,  Milani S., Pinzani  M. Eds. KluweracademicPublishers, Dordrecht;Falk 71:  279-303; 1994.    (senza IF)
  48. Mazzanti R., Fantappiè O., Fabrizio O., and Relli P. Susceptibility to lipid peroxidation of human hepatocellular carcinoma cell lines with different levels of multiple drug resistant phenotype. Lab. Invest. 73:419-423; 1995.  (IF:4,0)
  49. Mazzanti R., FantappièO., Fabrizio O., Pacini S., Relli P., Casamassima F., Milano F. and Ruggiero M. Conferringdrugresistance by MDR1 gene transfectionincreasessusceptibility to irradiation and lipidperoxidation in 3T3 cell line.  FreeRad. Biol. &Med. 20:601.606; 1996. (IF:5,533) 
  50. Mazzanti R, Fantappié O., Fabrizio P. The effect of development of the MDR1 phenotype on cell susceptibility to undergoing lipid peroxidation and ionizing radiation. In: New Trends in Hepatology. Gentilini P, and Dianzani MU. Eds. KluwerAcademicPublishers, Dordrecht, pgg 65-73; 1996.   (senza IF)
  51. P. Gentilini,Laffi G., Romanelli RG, Buzzelli  G, Casini Raggi V., Melani L., .Mazzanti R., et al.Clinical  course and prognostic elements of virus induced liver cirrhosis in Italian patients.  The Am. J. Gastroenterology  92:66-72; 1997. (IF:3,953)
  52. Mazzanti R., Messerini L., Monsacchi L, Buzzelli G, Zignego AL, Foschi M, Monti M, Laffi G,et al. Chronic viral hepatitis induced by HCV but not HBV infection correlates with increased liver angiogenesis. Hepatology,  25:229-234; 1997.  (IF:9,825)
  53. R. Duranti, G. Laffi, G. Misuri,D. Riccardi, M. Gorini, M. Foschi, I. Iandelli, R. Mazzanti,  M. Mancini, G. Scano, P. Gentilini. Respiratory mechanics in patients with tense cirrhotic ascites.  EurRespJ  10:1622-1630; 1997.  (IF :2,931)
  54. The CLIP group (Cancer of the Liver Italian Group) C. Gallo…..P. Gentilini,  R. Mazzanti,  et al..Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. The Lancet, 352; 17-20; 1998. (IF:15,397)
  55. T.Stroffolini,  P. Andreone, A. Andriulli, ..R. Mazzanti, et al. Characteristics of hepatocellular carcinoma in Italy. J. Hepatol. 29; 944-952; 1998. (IF: 4,974)
  56. T.Stroffolini, P. Andreone, A. Andriulli, ..R. Mazzanti, et al.. Gross pathologic types of  hepatocellular carcinoma in Italy. Oncology, 56; 189-192; 1999. (IF:2,330)
  57. The CLIP group, F. Perrone, B. Daniele, R. Mazzanti, et al…Prospective validation of the CLIP score, a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology, 31,  840-845, 2000. (IF:9,825)
  58. Bechi, P., Cianchi, F., Mazzanti R., Fantappié, O., Fiorillo, C., Nassi, P. Reflux and pH:”alcaline” components are not neutralized by gastric pH variations. Dis. Esophagus. 13; 51-55; 2000. (IF:0,603 )
  59. B. Neri, G. Cini, F. Andreoli, B. Boffi, D. Francesconi, R. Mazzanti, F. Medi., A. Mercatelli, S. Romano, L. Siliani, R. Tarquini, and R. Moretti. Randomised trial of adjuvant chemotherapy versus control after curative resection for gastric cancers:5-year follow-up.   B. J.Cancer84; 878-880; 2001. (IF:3,639)
  60. E. Masini, O. Fantappié, I. Sardi, L. Raimondi, V. Fabbroni,  PFMannaioni, and R. Mazzanti  Lipid peroxidation and cyclooxygenase-2 activity in human hepatocellular carcinoma cell lines  with and without multiple drug resistance:correlation with cell growth.. In :Advances in Prostaglandin and Leukotriene Research, Edited by Samuelsson B., Paoletti R., Folco GC, Granstrom E. and Nicosia S. Kluwer Academic Publishers, Dordrecht, 2001; pagg. 183-186. 
  61. Cianchi F., Cortesini C., Bechi P., Fantappiè O., Messerini  L., Vannacci A.,  Sardi I., Baroni  G.,  Boddi V.,  Mazzanti R.,  Masini E. Up – regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in  human colorectal cancer.  Gastroenterology,  121; 1339-1347; 2001. (I.F.: 13.440)
  62. FomusiNdisangJ., Wang R., Vannacci A., Marzocca C., Fantappié O., Mazzanti R.,Mannaioni PF. And Masini E. haeme oxygenase-1 as a novel target in the modulation of cardiac anaphylaxix.  Brit J Pharmacol ,134; 1689-1696, 2001. (I.F:3,450)
  63. FantappiéO., Masini E., Sardi I., Raimondi L., Bani D., Solazzo M., Vannacci A. and  Mazzanti R.  The multiple drug resistance phenotype is associated with the expression of COX-2 and iNOS in human hepatocellular carcinoma cell line. Hepatology35(4):843-52; 2002.(I.F.:9.825)
  64. Perrone F., Gallo C, Daniele B, … Mazzanti R. et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial.  Curr Pharm Des.8 (11):1013-9; 2002. (I.F:4,692).
  65. Cianchi F., Cortesini, C., Fantappié O, Mazzanti R., et Al.  Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol.162;793-801; 2003 (IF:6,750).
  66. Masini E., Vannacci A., ....Mazzanti R.  et al.   Heme oxygenase-1 and the ischemia-reperfusion injury in the rat heart. ExpBiol Med (Maywood). May;228(5):546-9; 2003. ( IF: 2,460)
  67. Daniele B., De Sio I., Izzo F.,...................Mazzanti R. et al. (CLIP Investigators) Hepatic 
  68. resection and Percutaneous ethanol injiection as tttreatments of small hepatocellular  carcinoma: a cancer of the Italian Liver Program (CLIP 08) retrospective case-control study.     J.ClinGastroenterol36; 63-67; 2003.(IF:1,357).
  69. Mazzanti R., Giallombardo AL, Mini E.,  et al.........  Treatment of  locally advanced hepatocellular carcinoma with  intra hepatic artery chemotherapy: a pilot study. Dig. LiverDis. 36(4); 278-285;2004. (IF:1,265)
  70. Cianchi F., Cortesini C., ...Mazzanti R. et al.  Cyclooxygenase-2 activation mediates the pathogenic effect of nitric oxide in colorectal  cancer. Clin Cancer Res.  10; 2694-2704; 2004. (IF:5,991).
  71. Vannacci A, Giannini L., ...Mazzanti R. et al. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. J PharmacolExpTher.  Oct;311(1):256-64. 2004. (IF:4,337)
  72. Fantappiè O., Lodovici M., ..Mazzanti R. Vitamin E protects DNA from oxidative damage in human hepatocellular carcinoma cell lines.  Free Radic Res.  Jul;38(7):751-9; 2004. (IF:2,743)
  73. Mazzanti R., Arena U., Pantaleo P., et al... Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: A 10-year experience. Can J Gastroenterol.  Oct;18(10):611-8; 2004. (IF:1,265).
  74. Cipriani G, Mazzanti R.   Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hand or simply a hope?  . Dig. Liver Dis. 37; 230-231; 2005 (IF 1,265).
  75. Fulignati C., Pantaleo P., Cipriani G, Turrini M. Nicastro R., Mazzanti R.,Neri B. An uncommon clinical presentation of retroperitoneal non Hodgkin lymphoma successfully  treated with chemotherapy: a case report. World J Gastroenterol 28; 3151-3155; 2005 (IF: 3).
  76. Darja Kanduc1*, JanGeliebter, Alberta Lucchese, Roberto Mazzanti, …………, Emanuel Farber.  Gene therapy in cancer: the missing point.   Journal of Experimental Therapeutics and Oncology, Vol. 5, pp. 151-158, 2005.
  77. Roberto Mazzanti ,Solazzo Michela, SquiresRachel, Fantappiè Ornella, Elfering Sarah,  Pantaleo Pietro, Bechi Paolo, Cianchi Fabio, and Giulivi Cecilia. Identification of potential target proteins in human colon cancer through expression proteomics. AmJ.Physiol, GastrointestLiverPhysiol 2006Jun;290(6):G1329-38.. (IF:3,479).
  78. Lasagna Nadia, Ornella Fantappiè, Michela Solazzo, Lucia Morbidelli, Serena Marchetti, Greta Cipraini, Marina Ziche and Roberto  Mazzanti. Hepatocyte Growth Factor and Inducible Nitric Oxide Synthase are Involved in Multiple Drug Resistance-Induced Angiogenesis in Hepatocellular Carcinoma Cell Lines, Cancer Res, 2006Mar 1;66(5):2673-82. (IF: 7,69)
  79. Neri B., Vannozzi L, …Mazzanti R. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.Cancer Invest. 2006 Aug-Sep;24(5):474-8. (IF 2,335)
  80. Solazzo M., FantappièO ….Mazzanti R. P-glycoprotein localization in mitochondria and its functional characterization in multiple drug resistant cell lines. Exp Cell Res  2006;312: 4070-4078.(IF:4,148) 
  81. Roberto Mazzanti ,Solazzo Michela, SquiresRachel, Fantappiè Ornella, Elfering Sarah,  Pantaleo Pietro, Bechi Paolo, Cianchi Fabio, and Giulivi Cecilia. Identification of potential target proteins in human colon cancer through expression proteomics. AmJ.Physiol, GastrointestLiverPhysiol 2006Jun;290(6):G1329-38.. (IF:3,479).
  82. Lasagna Nadia, Ornella Fantappiè, Michela Solazzo, Lucia Morbidelli, Serena Marchetti,Greta Cipriani, Marina Ziche and Roberto  Mazzanti. HepatocyteGrowthFactor andInducibleNitricOxideSynthase are Involved in Multiple DrugResistance-InducedAngiogenesis in Hepatocellular Carcinoma Cell Lines,Cancer Res, 2006Mar       1;66(5):2673-82.  (IF: 7,616)
  83. Mazzanti RobertoandGiulivi Cecilia  Coordination of nuclear and mithocondrial –DNA encoded proteins in cancer  and normal colon tissues.BiochimBiophysActa, 2006  May – Jun; 1757(5-6):618-23.  (IF: 4,302)
  84. Bolondi L,Piscaglia P…..Mazzanti R. et al. Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. ClinGastroenterolHepatol.2006 Aug 21;1395-1402.
  85. Oostendorp RL, Marchetti S., Bejinen JH ,Mazzanti R., Schellens JH. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinibmesylate.Cancer ChemotherPharmacol. 2007 May;59(6):855-60.  [Epub ahead of print] (IF:2,235)
  86. FantappièO.,  Solazzo M., Lasagna N.,  Platini F., Tessitore L,  Mazzanti R.P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug resistant cell lines. Cancer Res 2007 ;67:4915-4923; (IF:7,616)
  87. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH.Concise review: Clinical relevance of drug-drug and herb - drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).Oncologist. 2007 Aug;12(8):927-41. (I.F.=5,206)
  88. Mazzanti R, Messerini L, Comin CE, Fedeli L, Ganne-Carrie N, BeaugrandM.Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients.World J Gastroenterol. 2007 Oct 7;13(37):5009-14. (I.F=3,318)
  89. Fantappiè O., Lasagna N. Solazzo M., Neri B., and Mazzanti R. The multiple drug resistance phenotype and its consequences for cell biology of cancer cells. Res. Adv. In Cancer, 7; 127-137; 2007.
  90. Marchetti S., Mazzanti R.,Beijnen JH, and Schellens JM. Clinical relevance:drug-drug interaction,pharmacokinetics, pharmacodynamics and toxicity. In: Drug Transporters, Molecular Characterization and Role in Drug Disposition. Edited by: Guofeng You and Marilyn E. Morris. Wiley InterScience, Wiley &Sons Inc., Publication, pag. 747-880; 2007.
  91. Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH.  In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Mol Cancer Ther. 2007 Dec;6(12):3307-13. (IF:5,135).
  92. Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: Epidemiology and clinical aspects. Mol Aspects Med. 2008 Feb-Apr;29(1-2):130-43. (IF:7,386)
  93. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHEffect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.Mol Cancer Ther. 2008 Aug;7(8):2280-7 (IF:5,135).
  94. Mazzanti R, a,*, Francesca Platinib, Consuelo Bottinib, OrnellaFantappie` a,  MichelaSolazzoa, Luciana Tessitoreb. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. BiochemParmacol2009; 78; 21-32(IF: 4.838).
  95. Solazzo M, Fantappiè O, D'Amico M, Sassoli C, Tani A, Cipriani G, Bogani C,  Formigli L, Mazzanti R. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.Cancer Res. 2009 Sep15;69(18):7235-42. Epub 2009 Aug 25. (I.F.= 7,514).
  96. Kanduc D, Novello G, Mazzanti R.P-170 peptides with low similarity to the human proteome: tracing an effective and safe biological way towards effective and safe cancer chemotherapy.J ExpTherOncol. 2009;8(2):151-5.
  97. Baldazzi V, Tassi R,Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study. UrolOncol. 2012 Sep; 30(5) 704-710(IF= 2.53).
  98. Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis.Baldazzi V, Tassi R, Lapini A, Lunghi A, Garofoli E, Caruso S, Carini M, Mazzanti R.  Cancer. 2012 Jun 15; 118 (12) 3165-3172. doi: 10.1002/cncr.26435. (I.F.= 5.131).
  99. Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R,Beijnen JH, Schellens JH.Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Invest New Drugs. 2013 Oct; 31(5):1125-1135. Doi 10.1007/s10637-013-9923-1.
  100. Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R,Schellens JH, Beijnen JH, van Tellingen O.Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clin Cancer Res. 2013 Apr 15;19(8):2084-95. doi: 10.1158/1078-0432.CCR-12-3105. Epub 2013 Mar 5.
  101. Bracarda S. Gernone A., Gasparro D, …….Mazzanti R., et al…. Real world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 2014 May; 10 (6) 975-983. Doi:102217/fon.13.256.
  102. Bajetta E., Floriani I, Di Bartolomeo M., and ITACA- S Study group. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5- Fluorouracil and folic acid for radically resected gastric cancer. Ann Oncol 2014 Jul; 25(7):1373-8. Doi:10.1093/annonc/mdu146.
  103. Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the drug transporters ABCB1, ABCC2 and ABCG2 on the disposition and brain accumulation of the taxanes analog BMS-275, 183. Invest New drugs 2014 Dec; 32(6):1083-1095. doi:10.1007/s10637-014-0143-0.
  104. Sardi I, Fantappiè O, la Marca G, …Mazzanti R. Delivery of doxorubicin across the blood –brain-barrier by ondansetron pretreatment: a study in vitro and in vivo.CancerLett. 2014 Oct 28;353(2):242-7. doi: 10.1016/j.canlet.2014.07.018
  105. Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events? ClinGentitourinCancer  2015 Apr; 13 (2):e101-105.doi 10.1016/j.clgc.2014.08.009.
  106. Fantappiè O, Sassoli C, Tani A, Nosi D, Marchetti S, Formili L, Mazzanti R.  Mitochondria of a human multidrug resistant hepatocellular carcinoma cell–line constitutively express inducible nitric oxide synthase in the inner membrane.J Cell Mol Med. 2015 Jun; 19 (6) 1410-7.doi:101111/jcmm.12528.
  107. Mazzanti R, Arena U, Tassi R.  Hepatocellular carcinoma: Where are we? World J Exp Med 2016 Feb20;6(1):21-36.doi:10.5493/wjem.v6.i1.21. Review.


surgery-open-access Journal Flyer